Bextra “Dear Doctor” letter
Executive Summary
Pfizer/Pharmacia send "Dear Doctor" letter Nov. 13 alerting physicians to new warnings and a contraindication in Bextra labeling against use in patients with demonstrated allergic-type reactions to sulfonamides. The companies first alerted prescribers to the issue in October; revised labeling was approved by FDA Nov. 1 (1"The Pink Sheet" Nov. 11, p. 19)...
You may also be interested in...
Pfizer/Pharmacia Bextra Adds Hypersensitivity And Skin Reaction Warnings
Pfizer and Pharmacia will be alerting physicians to a new warning statement in Bextra (valdecoxib) labeling about skin and hypersensitivity reactions to the COX-2 inhibitor
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.